ESMO 2024 Insights: Real-World Evidence of Recurrence Risk in Node- and Node+ HR+/HER2- eBC From US Electronic Health Records

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Find latest Breast videos · 900+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Real-World Evidence of Recurrence Risk in Node- and Node+ HR+/HER2- eBC From US Electronic Health Records

By 2024 ESMO Annual Meeting Insights Hub FEATURING Komal Jhaveri

354 views

October 17, 2024

Comments 0

2024 ESMO Annual Meeting Insights Hub: Breast Videos

ESMO 2024 Insights: Identification of Racial Disparities Across Mamm…

2024 ESMO Annual Meeting Insights Hub

W. Audeh

52 views

Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Sacit…

2024 ESMO Annual Meeting Insights Hub

A. Brufsky

48 views

ESMO 2024 Insights: Adjuvant Ribociclib + NSAI in HR+/HER2- eBC - 4-…

2024 ESMO Annual Meeting Insights Hub

P. Fasching

94 views

View All

Oncology Clinical Updates - Review and Renew

Sat, Apr 5, 2025

SABCS 2024 Insights: DESTINY-Breast06 - Monday Morning Practice

2024 SABCS Annual Meeting Insights Hub

S. Tolaney, H. Rugo

2.2K views

Year in Review 2024: Top Metastatic Breast Cancer Trials

Oncology 2024 Year in Review

V. Kaklamani

1.7K views

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

2.3K views

SABCS 2024 Noteworthy Abstracts in Metastatic Breast Cancer

Sara Tolaney

H. Rugo

1.4K views

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

1.2K views

SABCS 2024 Summary: Key Updates From the EMBER-3, PATINA, TAILORx, I…

2024 SABCS Annual Meeting Insights Hub

M. Gatti-Mays

994 views

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

5.2K views

SABCS 2024 Noteworthy Abstracts in Early Breast Cancer

Sara Tolaney

H. Rugo

1.1K views

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

1.5K views

SABCS 2024 Insights: PATINA - Monday Morning Practice

2024 SABCS Annual Meeting Insights Hub

S. Tolaney, H. Rugo

665 views

SABCS 2024 Summary: mBC Key Trial Highlights Including PATINA and EM…

2024 SABCS Annual Meeting Insights Hub

A. Brufsky

601 views

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.5K views

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.9K views

SABCS 2024 Summary: Key Trials Including EMBER-3 & TAILORx

2024 SABCS Annual Meeting Insights Hub

V. Kaklamani

482 views

Male Breast Cancer

Kathryn J. Ruddy

551 views

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

2.4K views

SABCS 2024 Insights: EMBER-3 - Monday Morning Practice

2024 SABCS Annual Meeting Insights Hub

S. Tolaney, H. Rugo

505 views

SABCS 2024 Insights: Impact of Ribociclib Dose Reduction on Efficacy…

2024 SABCS Annual Meeting Insights Hub

E. Hamilton

368 views

SABCS 2024 Summary: eBC Highlights Including GeparDouze & OlympiA

2024 SABCS Annual Meeting Insights Hub

S. Tolaney, H. Rugo

518 views

The 2023 ASCO®/CAP Guideline Update on HER2 Testing/Classification: …

Shabnam Jaffer

1.1K views

AUTOPLAY

Login

Login

Join VuMedi

ESMO 2024 Insights: Real-World Evidence of Recurrence Risk in Node- and Node+ HR+/HER2- eBC From US Electronic Health Records

2024 ESMO Annual Meeting Insights Hub: Breast Videos

ESMO 2024 Insights: Identification of Racial Disparities Across Mamm…

Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Sacit…

ESMO 2024 Insights: Adjuvant Ribociclib + NSAI in HR+/HER2- eBC - 4-…

Related Videos

Oncology Clinical Updates - Review and Renew

SABCS 2024 Insights: DESTINY-Breast06 - Monday Morning Practice

Year in Review 2024: Top Metastatic Breast Cancer Trials

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

SABCS 2024 Noteworthy Abstracts in Metastatic Breast Cancer

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

SABCS 2024 Summary: Key Updates From the EMBER-3, PATINA, TAILORx, I…

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

SABCS 2024 Noteworthy Abstracts in Early Breast Cancer

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

SABCS 2024 Insights: PATINA - Monday Morning Practice

SABCS 2024 Summary: mBC Key Trial Highlights Including PATINA and EM…

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

SABCS 2024 Summary: Key Trials Including EMBER-3 & TAILORx

Male Breast Cancer

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

SABCS 2024 Insights: EMBER-3 - Monday Morning Practice

SABCS 2024 Insights: Impact of Ribociclib Dose Reduction on Efficacy…

SABCS 2024 Summary: eBC Highlights Including GeparDouze & OlympiA

The 2023 ASCO®/CAP Guideline Update on HER2 Testing/Classification: …